5 results found.

Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Sta Clinical Trial using dabrafenib; ipilimumab; trametinib; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Sequential Safety and Biomarker Study of BRAF-MEK Inhibition on the Immune Response in the Context of CTLA-4 Blockade for BRAF Mutant Melanoma.
dabrafenib; ipilimumab; trametinib; laboratory biomarker analysis

Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Sta Clinical Trial using cyclophosphamide; fludarabine phosphate; therapeutic tumor infiltrating lymphocytes; aldesleukin; laboratory biomarker analysis

Fred Hutchinson Cancer Research Center - Recruiting 18 years or older.
- Cellular Adoptive Immunotherapy Using Autologous Tumor-Infiltrating Lymphocytes Following Lymphodepletion With Cyclophosphamide and Fludarabine for Patients With Metastatic Melanoma.
cyclophosphamide; fludarabine phosphate; therapeutic tumor infiltrating lymphocytes; aldesleukin; laboratory biomarker analysis

Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Sta Clinical Trial using dabrafenib; trametinib; navitoclax; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase I/II Study of Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma and Other Solid Tumors.
dabrafenib; trametinib; navitoclax; pharmacological study; laboratory biomarker analysis

Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Sta Clinical Trial using ipilimumab; recombinant interferon alfa-2b; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Randomized Phase II Study of Ipilimumab at 3 mg/kg or 10 mg/kg Alone or in Combination With High Dose Interferon-Alpha in Advanced Melanoma.
ipilimumab; recombinant interferon alfa-2b; laboratory biomarker analysis

Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Sta Clinical Trial using riluzole; sorafenib tosylate; diagnostic laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I Trial of Riluzole and Sorafenib in Patients With Advanced Solid Tumors and Melanoma.
riluzole; sorafenib tosylate; diagnostic laboratory biomarker analysis; pharmacological study